Navigating The Pending BIOSECURE Act: Implications For U.S.-China Biopharmaceutical Collaboration And National Security - New Technology

The BIOSECURE Act (H.R. 7085), which has the potential to severely restrict the ability of U.S. biopharmaceutical companies to collaborate with certain Chinese entities without losing the ability to contract with the U.S. government, has made headlines in recent weeks.

Related Keywords

China ,Washington ,United States ,North Carolina ,American ,Chinese ,Dorothy Chen ,Janet Yellen ,Lloyd Austin ,Gina Raimondo ,Gary Peters ,Accountability Committee ,Department Of Treasury ,Senate Homeland ,House Select Committee ,Office Of Management ,Industrial Complex Companies List ,National Defense Authorization ,Department Of Commerce Bureau Industry ,House Armed Services Committee ,Chinese Communist Party ,Defense Chinese Military Companies List ,Department Of Defense ,Government Affairs Committee ,Party China Select Committee ,China Select Committee ,Complete Genomics ,Wuxi Apptec ,Chinese Communist ,Chairman Mike Gallagher ,Ranking Member Raja Krishnamoorthi ,Federal Acquisition Regulatory ,Federal Acquisition Regulations ,Defense Authorization Act ,Bill Hagerty ,Commerce Secretary Gina Raimondo ,Defense Secretary Lloyd Austin ,Treasury Secretary Janet Yellen ,Wuxi Biologics ,Chinese Military Companies List ,Security Entity ,Military Industrial Complex Companies ,House Oversight ,Select Committee ,Congressman Gallagher ,Mondaq ,Navigating The Pending Biosecure Act Implications For Us China Biopharmaceutical Collaboration And National Security ,Media ,Elecoms ,It ,Entertainment ,Telecoms ,Obile Amp Cable Communications ,Technology ,New Technology , ,